This inventor holds 7 USPTO granted patents. Top assignee: Glaxo Group Limited. Active years: 1986-2002.
Location History:
- Meldreth, GB (1986 - 1989)
- Cambridge, GB (1996)
- Middlesex, GB (2000)
- Uxbridge, GB (1999 - 2002)
Company Filing History:
Years Active: 1986-2002
Title: The Innovations of John M. Padfield: A Pioneer in Migraine Treatment
Introduction: John M. Padfield, an accomplished inventor based in Meldreth, GB, has made significant contributions to the pharmaceutical industry with his innovative approaches to treating migraines. With a total of 7 patents to his name, Padfield stands out as a key figure in the development of effective solutions for cephalic pain.
Latest Patents: Among Padfield's latest innovations is a groundbreaking pharmaceutical composition aimed at treating migraines. This composition features a unique film-coated solid dosage form that includes 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as the active ingredient. The patent outlines that these dosage forms are particularly useful in alleviating conditions associated with cephalic pain, specifically targeting migraine sufferers.
Career Highlights: John M. Padfield has established his career within the esteemed Glaxo Group Limited, where his work focuses on creating pioneering pharmaceutical solutions. His expertise and dedication have earned him recognition in the field, contributing significantly to advancements in migraine treatment.
Collaborations: Throughout his career, Padfield has collaborated with notable colleagues, including Anthony John Phillips and Ian Keith Winterborn. These collaborations have allowed for the exchange of innovative ideas and the development of effective pharmaceutical compositions, further enhancing the impact of their work.
Conclusion: As an inventor, John M. Padfield exemplifies the spirit of innovation in the pharmaceutical sector. His latest patents demonstrate a commitment to improving the quality of life for those suffering from migraines, solidifying his legacy as a prominent figure in the field. With ongoing collaborations and a strong foundation at Glaxo Group Limited, Padfield's contributions are sure to influence future advancements in medical treatments.